Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FMP011 is a recombinant protein vaccine candidate designed to prevent malaria caused by *Plasmodium falciparum*. Developed by the Walter Reed Army Institute of Research (WRAIR), the vaccine consists of a nearly full-length circumsporozoite protein (CSP) expressed in *Escherichia coli*. CSP is the dominant surface protein of the malaria sporozoite and is critical for the parasite's entry into hepatocytes. FMP011 is typically formulated with the Army Liposome Formulation containing QS-21 (ALFQ) to enhance the immune response, specifically targeting the induction of high-titer antibodies and cellular immunity against the pre-erythrocytic stage of the parasite.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FMP011.